Chemokines are critical for the inflammatory process in autoimmune diseases such as rheumatoid arthritis (RA). The chemokine receptor-5 (CCR5) mediates chemotaxis by CC-chemokines and is expressed by lymphocytes with the Th1 phenotype and monocyte/macrophages. A 32 bp deletion in the CCR5 (CCR5-⌬32 allele) abolishes receptor expression in homozygotes, while CCR5-⌬32 carriers would express less receptor than wild-type homozygotes. This polymorphism is related to the resistance to HIV-1 infection and progression towards AIDS. We hypothesized that the CCR5-⌬32 allele may modulate the severity of disease in RA. A total of 160 RA-patients (71 and 89 with severe and non-severe phenotypes, respectively) and 500 healthy individuals from the same Caucasian population (Asturias, northern Spain) were genotyped. Carriers of the CCR5-⌬32 allele were at a significantly higher frequency (P = 0.012) in non-severe compared to severe patients (17% vs 4%). Our results suggest that the CCR5-⌬32 polymorphism is a genetic marker related to the severity of RA. Genes and Immunity (2000) 1, 288-289.
Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease of the joints characterized by the infiltration of the synovial membrane with T lymphocytes and macrophages, and pannus formation over the underlying cartilage and bone. The inflammatory process observed in RA is mediated by chemotactic factors released by the inflamed tissues. Chemokines display a potent chemotactic activity for cells of the immune system, playing an important role in both the destructive and the fibrovasculoproliferative phases of RA. 1 The chemokine receptor-5 (CCR5) mediates chemotaxis by the CC-chemokines RANTES, MIP-1␣ and MIP-1␤. This receptor is expressed by lymphocytes exhibiting the Th1-phenotype and by monocytes/macrophages. 2 In addition to its role in inflammation, CCR5 also acts as an HIV-1 coreceptor to mediate the first step in cell entry:fusion of the viral envelope with the membrane in the the target CD4 + cell. A 32 bp deletion at the coding region of the CCR5 gene, the CCR5-⌬32 mutation, leads to the expression of reduced amounts of the CCR5 protein in heterozygous individuals.
3 CCR5-⌬32 homozygotes do not express the receptor and have nearly complete resistence to HIV-1 infection despite repeated exposure, while heterozygotes progress slowly towards AIDS compared to wild-type homozygotes. 4 The CCR5- ⌬32 allele is common among Caucasians, but was not found in native African, American Indian and East Asian ethnic groups. 5 RANTES, one of the CCR5 ligands, is found in the rheumatoid synovium and would play a role in the pathogenesis of RA. In addition, CCR5 is strongly expressed on T-lymphocytes from the synovial fluid of RA patients. 6, 7 Thus, it might be possible that CCR5 is involved in the recruitment of inflammatory cells into the inflamed tissue, and any mechanism modulating the CCR5 expression could have an effect in the development of RA. In this way, a reduced expression of this receptor on lymphocytes and macrophages could attenuate the severity of the disease. Here, we investigated whether the CCR5-⌬32 allele has an effect on the severity of RA. DNA was obtained from 160 consecutive unrelated patients (119 women, 41 men) diagnosed according to the revised criteria of the American College of Rheumatology. 8 Patients were eligible if the disease duration was Ͼ3 years. The average age of patients was 58.12 years (±13.05) and the mean disease duration was 9.13 years (±6.05). RA was defined as early-severe or non-severe according to the criteria of Zeidler et al. 9 Patients with early-severe RA had early (Ͻ3 years) with juxta-articular erosions visible on X-ray, or disease failing to respond to a second line antiırheumatic drug, or two of the following characteristics: (1) a positive assay for rheumatoid factor; (2) an ESR of Ͼ40 mm/h or CRP of Ͼ40 mg/l; (3) anaemia (haemoglobin Ͻ110 g/l). A total of 71 and 89 patients were included in the early-severe and non-severe groups, respectively. The average age were 56.61 years (±11.80) for early-severe and 59.36 years (±13.85) for the non-severe group. We also genotyped 500 healthy con- Patients and controls were from the same homogenous Caucasian population (Asturias, northern Spain, total population 1 million) and gave their consent to participate in the study. The CCR5-⌬32 polymorphism was analysed as previously described. 4 Genotypes and allele frequencies were compared through a Yates 2 test. In our control population the CCR5-⌬32 frequency was similar to that found in other Caucasian populations. 4, 5 The frequency of CCR5-⌬32 carriers was lower in the whole RA population (11%) compared to controls (17%). However, this difference did not reach statistical significance (P = 0.059) . This is in agreement with recent reports that described a reduced frequency of CCR5-⌬32 among patients with RA. 10, 11 In addition, none of the patients were homozygous for the CCR5-⌬32 allele, a fact that would suggest a resistance to develop RA among these individuals. However, the notion that CCR5-⌬32 homozygotes are resistant to RA was challenged by two recent reports that described four homozygotes out of 441 RA patients. 10, 12 Only three out of the 71 (4%) patients with the early-severe phenotype carried the ⌬32-allele compared to 15 out of the 89 (17%) patients with the nonsevere form (Table 1) . The difference between both groups of patients was significant (P = 0.012). Additionally, a significant difference was found between patients with the early-severe phenotype and healthy controls (P = 0.0056).
The local production of chemokines (RANTES, MIP-1␣, MCP-1, IL-8) by synovial cells drives the transendothelial migration of leukocytes toward the inflammatory site. Thus, the level of chemokine receptors could determine the amount of leukocytes in the synovial fluid and the degree of the inflammatory response. Carriers of the CCR5-⌬32 allele have a reduced expression of the receptor on the cell surface, a fact that could imply a reduced inflammatory response in mutation carriers compared to wild-type homozygotes. 2 In conclusion, our data indicate that the genetic variation at the CCR5 locus plays a role in the clinical course of RA. This is in accordance with a previous work describing that antibodies to human RANTES ameliorate the disease severity in the rat adjuvant-induced arthritis model. 13 Taken together, these data suggest that the treatment with chemokine-receptor antagonists could be a valuable therapy for retarding joint destruction in RA. However, it is well established that RA is a multifactorial disease, and variation in other genes (HLA DRB1, IL-1, etc) would modulate disease severity. 14, 15 Further studies are necessary to confirm the association between variation at the the CCR5 gene and RA and to define the interaction between cytokine, chemokine and HLA genes in the development of RA.
